


PHARMACEUTICAL 2023

Nascent Biotech Inc. Rank 423 of 446









Nascent Biotech Inc. Rank 423 of 446



The relative strengths and weaknesses of Nascent Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nascent Biotech Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 179% points. The greatest weakness of Nascent Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 379% points.

The company's Economic Capital Ratio, given in the ranking table, is -368%, being 412% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	105
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	777
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,457
Other Liabilities	0
Other Net Income	-13
Other Revenues	1,000
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	105
Liabilities	777
Expenses	1,457
Revenues	1,000
Stockholders Equity	-671
Net Income	-470
Comprehensive Net Income	-470
Economic Capital Ratio	-368%

